JWM
BMRN icon

Jacobus Wealth Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Jacobus Wealth Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-1,437
Closed -$104K – 299
2014
Q3 		$104K Buy
+1,437
New +$94.4K 0.03% 295

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

Jacobus Wealth Management's BMRN Position: Q4 2014 in Review

Jacobus Wealth Management sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2014, closing a stake of 1,437 shares — an estimated $104K sold.

Jacobus Wealth Management first reported a position in BMRN in Q3 2014 and held it in 1 quarter. The position peaked at $104K in Q3 2014. 341 funds tracked by Wall St. Rank hold BMRN as of Q4 2014.

  • Jacobus Wealth Management reported no remaining BioMarin Pharmaceuticals position as of Q4 2014 after selling out during the quarter.
  • Jacobus Wealth Management sold 1,437 BioMarin Pharmaceuticals shares in Q4 2014, an estimated $104K.
  • Jacobus Wealth Management first reported a position in BioMarin Pharmaceuticals in Q3 2014 and held it in 1 quarter.
  • Jacobus Wealth Management's BioMarin Pharmaceuticals position peaked at $104K in Q3 2014.
  • 341 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2014.

Based on Jacobus Wealth Management's 13F filing for Q4 2014, filed 6 Feb 2015.